Tanaka Shinji
Department of Molecular Oncology, Tokyo Medical and Dental University, Tokyo, Japan.
Ann Surg Oncol. 2016 Feb;23 Suppl 2:S197-205. doi: 10.1245/s10434-015-4463-x. Epub 2015 Mar 7.
Accumulation of multiple genetic and/or epigenetic abnormalities is required for generation and progression of cancers, and the survival of cancer cells might depend on addiction to these abnormalities. Because disruption of such dependency on the abnormal molecules should cause the cancer cell death, so-called oncogene addiction is the rationale for molecular targeted therapy. Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is one of the most lethal malignancies in humans, and remains a challenging problem in targeted therapy compared to other malignancies such as pancreatic neuroendocrine tumor. This review summarizes the molecular pathogenesis of pancreatic cancer on the basis of the recent studies of driver mutations including chromatin remodeling factors, and promising concepts "cancer stemness" and "stromal niche" for the strategy of novel targeted therapy.
癌症的发生和进展需要多种遗传和/或表观遗传异常的积累,癌细胞的存活可能依赖于对这些异常的依赖。由于破坏对异常分子的这种依赖性会导致癌细胞死亡,因此所谓的癌基因成瘾是分子靶向治疗的理论基础。胰腺癌,尤其是胰腺导管腺癌,是人类最致命的恶性肿瘤之一,与其他恶性肿瘤如胰腺神经内分泌肿瘤相比,在靶向治疗方面仍然是一个具有挑战性的问题。本文基于对包括染色质重塑因子在内的驱动突变的最新研究,总结了胰腺癌的分子发病机制,以及针对新型靶向治疗策略的有前景的概念“癌症干性”和“基质微环境”。